TNXP Earnings Date: Nov 9, 2026 (Estimated) — Tonix Pharmaceuticals Holding Corp.
NASDAQ
Updated
When is TNXP's next earnings date?
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$2.39 on revenue of $16.3M.
How did TNXP do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Tonix Pharmaceuticals Holding Corp. posted EPS of -$2.44 versus the -$2.64 estimate, a beat of 7.6%. Revenue was $13.5M against a $7.7M estimate. The stock's 1-day post-earnings move was +4.7%.
How much does TNXP stock move after earnings?
TNXP beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.9% (up or down) in the day after earnings.
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -2.64 | -2.44 | +7.58% | $13.5M | ✅ Beat | +4.66% | +5.65% | +9.39% |
| 2026-05-11 | Q1 2026 | -2.51 | -2.93 | -16.73% | $6.9M | ❌ Miss | -5.88% | +1.06% | -22.32% |
| 2026-03-12 | Q4 2025 | -3.03 | -3.98 | -31.35% | $5.4M | ❌ Miss | -1.27% | +17.60% | -3.21% |
| 2025-11-10 | Q3 2025 | -3.09 | -3.59 | -16.18% | $3.3M | ❌ Miss | -0.94% | -6.47% | +15.29% |
| 2025-08-11 | Q2 2025 | -2.37 | -3.86 | -62.87% | $2.0M | ❌ Miss | +32.89% | -10.90% | -39.98% |
| 2025-03-18 | Q4 2024 | -768.00 | -9.77 | +98.73% | $2.6M | ✅ Beat | -19.78% | +45.01% | -22.75% |
| 2024-08-16 | Q2 2024 | -720.00 | -1928.00 | -167.78% | $2.2M | ❌ Miss | -0.54% | -24.01% | -67.14% |
| 2024-05-13 | Q1 2024 | -1248.00 | -576.00 | +53.85% | $2.5M | ✅ Beat | +5.20% | +11.05% | -79.73% |
Showing last 8 quarters.